5, 25 mg in glass bottle
Bioymifi induces apoptosis via the Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) death receptor DR5 independent of TRAIL. Bioymifi binds selectively to the extracellular domain of DR5 with little binding affinity to DR4, promoting DR5 aggregation and activation. Bioymifi caused apoptosis and cell death in a variety of human cancer cell lines including T98G human glioblastoma cells, lung cancer cell lines H460 and H1155, the cervical cancer cell line HeLa, the osteosarcoma cell line U2OS, the pancreatic carcinoma cell line Miapaca and the colon cancer cell line HT29.
Bioymifi通过独立于TRAIL的肿瘤坏死因子（TNF）相关凋亡诱导配体（TRAIL）死亡受体DR5诱导凋亡。 Bioymifi选择性地与DR5的胞外域结合，对DR4的结合亲和力很小，从而促进了DR5的聚集和激活。 Bioymifi导致多种人类癌细胞系的凋亡和细胞死亡，包括T98G人类胶质母细胞瘤细胞，肺癌细胞H460和H1155，宫颈癌细胞HeLa，骨肉瘤细胞U2OS，胰腺癌细胞系Miapaca和结肠 癌细胞系HT29。
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
|Quality Level ||100|
|assay ||≥98% (HPLC)|
|color ||orange to dark orange red|
|solubility ||DMSO: 2 mg/mL, clear (warmed)|
|storage temp. ||2-8°C|
RIDADR NONH for all modes of transport